Tag: Brentuximab Vedotin
Phase III Clinical Trials of Brentuximab Vedotin Continue to Demonstrate Superior...
Additional, updated, analyses of results from ECHELON-1 and ECHELON-2, the frontline phase III trials of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda), an antibody-drug conjugate or...
ASH 2018 Highlights Progress in Ongoing Development of Brentuximab Vedotin
As the premier hematology event in malignant and non-malignant hematology, the annual meeting of the American Society of Hematology (ASH), held this year from...
Supplemental Biologics License Application for Brentuximab Vedotin in Frontline Treatment of...
Seattle Genetics has submitted a supplemental Biologics License Application (BLA) for brentuximab vedotin (Adcetris®) to the U.S. Food and Drug Administration (FDA). The submission is...
Four Ways to Show Nonobviousness of ADC Inventions
As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.
New Hydrophilic Auristatin Payload Improves Antibody-Drug Conjugate Efficacy and Biocompatibility
Antibody-drug conjugates or ADCs, which link an antibody to a potent, small-molecule, cytotoxic, cell-killing, chemotherapeutic agent, use the target-specificity of monoclonal antibodies or antibody...
AACR 2018: Highlighting Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology
This year, the American Association for Cancer Research (AACR) will host their annual meeting April 14 - 18, 2018 in the McCormick Place North/South...
Brentuximab Vedotin in Combination with Chemotherapy Approved for Adults with Previously...
The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) in combination with chemotherapy in adult patients with previously untreated...
Brentuximab Vedotin Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma...
The European Commission has extended the current conditional marketing authorization for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to include the treatment of adult patients with...
The Expanding Field of Antibody-Drug Conjugates
Antibody-drug conjugates or ADCs have emerged as a powerful and strategy tool in the targeted treatment of cancer. These relatively novel agents combine the...
U.S. FDA Grants Priority Review for Brentuximab Vedotin in Frontline Advanced...
Based on positive results from the Phase III ECHELON-1 clinical trial, the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental...
